To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recruiting · NCT05442060 · Registry updated 2025-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2025-08-03 | NCT05442060 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OBI Pharma, Inc | 4 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Linkou Chang Gung Memorial Hospital | Taoyuan | Taiwan | 1 |
| National Taiwan University Cancer Center | Taipei | Taiwan | 1 |
| National Taiwan University Hospital | Taipei | Taiwan | 3 |
| Shuang Ho Hospital | New Taipei City | Taiwan | 1 |
| Taichung Veterans General Hospital | Taichung | Taiwan | 111 |
| Taipei Veterans General Hospital | Taipei | Taiwan | 5 |
| Tri-Service General Hospital | Taipei | Taiwan | 1 |